OBR Green Articles (ASCO Conference Coverage)

article

June 2019Edition

Four standout studies were among this year’s most notable at ASCO. For certain patients with pancreatic, head-and-neck cancer, bladder and prostate cancers, the data presented redefined optimal therapy....

article

June 2019Edition

What's next for cell therapy? At ASCO, cutting edge, earlier stage studies such as Iovance’s data on TILs in cervical cancer and melanoma, Moderna's neoantigen vaccine, and CAR-T cells moving into solid tumors like mesothelioma generated buzz and ...

article

June 2019Edition

Physician experts share their thoughts on some of the key studies emerging from this year's ASCO and talk about why they made such an impact....